Furthermore, the combination of p300/CBP inhibitors and quizartinib had synergistic effects on these FLT3-ITD+ AML samples, as evidenced by markedly low CI values ranging from 0.30 to 0.52 (Fig. 6c). Here, EP300 is linked to acute myeloid leukemia.